| Product Code: ETC6177183 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Overview |
3.1 Australia Country Macro Economic Indicators |
3.2 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, 2021 & 2031F |
3.3 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market - Industry Life Cycle |
3.4 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market - Porter's Five Forces |
3.5 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume Share, By Drug Type, 2021 & 2031F |
3.6 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume Share, By Product Type, 2021 & 2031F |
3.7 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.8 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume Share, By Diagnosis, 2021 & 2031F |
3.9 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume Share, By Treatment, 2021 & 2031F |
3.10 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of chronic obstructive pulmonary disease (COPD) in Australia |
4.2.2 Growing awareness about COPD and its management |
4.2.3 Technological advancements leading to the development of innovative COPD drugs |
4.3 Market Restraints |
4.3.1 Stringent regulations and approval processes for new COPD drugs |
4.3.2 High costs associated with COPD drug development and treatment |
4.3.3 Competition from alternative treatment options like inhalers and pulmonary rehabilitation programs |
5 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Trends |
6 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market, By Types |
6.1 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market, By Drug Type |
6.1.1 Overview and Analysis |
6.1.2 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Drug Type, 2021- 2031F |
6.1.3 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Phosphodiestrase-4 Inhibitors, 2021- 2031F |
6.1.4 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Long-Acting Bronchodilators, 2021- 2031F |
6.1.5 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Short-Acting Bronchodilators, 2021- 2031F |
6.1.6 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Methylxanthines, 2021- 2031F |
6.1.7 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Corticosteroids, 2021- 2031F |
6.2 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market, By Product Type |
6.2.1 Overview and Analysis |
6.2.2 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Inhalers, 2021- 2031F |
6.2.3 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Nebulizers, 2021- 2031F |
6.3 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market, By Type |
6.3.1 Overview and Analysis |
6.3.2 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Chronic Bronchitis, 2021- 2031F |
6.3.3 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Emphysema, 2021- 2031F |
6.4 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market, By Diagnosis |
6.4.1 Overview and Analysis |
6.4.2 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Pirometry, 2021- 2031F |
6.4.3 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Diagnostic Tests, 2021- 2031F |
6.4.4 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Others, 2021- 2031F |
6.5 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market, By Treatment |
6.5.1 Overview and Analysis |
6.5.2 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Oxygen Therapy, 2021- 2031F |
6.5.3 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Lung Transplant, 2021- 2031F |
6.5.4 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Drug Therapy, 2021- 2031F |
6.5.5 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Vaccination, 2021- 2031F |
6.5.6 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Surgery, 2021- 2031F |
6.5.7 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Others, 2021- 2031F |
6.6 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market, By End User |
6.6.1 Overview and Analysis |
6.6.2 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Hospitals & Clinics, 2021- 2031F |
6.6.3 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Home Care Settings, 2021- 2031F |
6.6.4 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Others, 2021- 2031F |
7 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Import-Export Trade Statistics |
7.1 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Export to Major Countries |
7.2 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Imports from Major Countries |
8 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Key Performance Indicators |
8.1 Number of COPD patients diagnosed annually |
8.2 Adoption rate of new COPD drug therapies |
8.3 Patient adherence and compliance to COPD drug regimens |
9 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market - Opportunity Assessment |
9.1 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Opportunity Assessment, By Drug Type, 2021 & 2031F |
9.2 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Opportunity Assessment, By Product Type, 2021 & 2031F |
9.3 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Opportunity Assessment, By Type, 2021 & 2031F |
9.4 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Opportunity Assessment, By Diagnosis, 2021 & 2031F |
9.5 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Opportunity Assessment, By Treatment, 2021 & 2031F |
9.6 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Opportunity Assessment, By End User, 2021 & 2031F |
10 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market - Competitive Landscape |
10.1 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenue Share, By Companies, 2024 |
10.2 Australia Chronic Obstructive Pulmonary Disease (COPD) Drug Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here